Financial Performance - Canopy Growth reported net revenue of CAD 268.995 million for the year ended March 31, 2025, a decrease of 9% from CAD 297.146 million in 2024 [449]. - The gross margin percentage improved to 30% in fiscal 2025, up from 27% in fiscal 2024, reflecting strategic changes and cost savings initiatives [458]. - Net loss from continuing operations increased to CAD 604.138 million in fiscal 2025, compared to CAD 483.682 million in 2024, representing a 25% increase in losses [449]. - Canadian adult-use cannabis revenue decreased by 15% to CAD 78.828 million in fiscal 2025, primarily due to lower sales volumes and increased price competition [451][453]. - Canadian medical cannabis revenue increased by 16% to CAD 77.032 million in fiscal 2025, driven by a higher average order size and a larger product assortment [451][454]. - International markets cannabis revenue decreased by 4% to CAD 39.734 million in fiscal 2025, attributed to declines in the Australian market and U.S. CBD business [451][455]. - Revenue from Storz & Bickel increased by 4% to CAD 73.401 million in fiscal 2025, supported by strong sales growth in Germany and the UK [451][456]. - The divestiture of This Works on December 18, 2023, resulted in a complete revenue loss from this segment, which was CAD 21.256 million in fiscal 2024 [451][457]. - Cost of goods sold decreased by 12% to CAD 189.484 million in fiscal 2025, contributing to the improved gross margin [458]. - Canopy Growth's weighted average number of outstanding common shares increased to 107,553,729 in fiscal 2025, up from 74,787,521 in fiscal 2024 [449]. Operating Expenses - Total operating expenses decreased to $196.7 million in fiscal 2025, down 36% from $309.6 million in fiscal 2024 [465]. - General and administrative expenses were $65.1 million in fiscal 2025, a 28% decrease from $90.3 million in fiscal 2024 [467]. - Sales and marketing expenses dropped to $60.9 million in fiscal 2025, down 20% from $76.1 million in fiscal 2024 [468]. - The company incurred acquisition-related costs of $19.5 million in fiscal 2025, down from $34.8 million in fiscal 2024, reflecting ongoing restructuring efforts [469]. - Total restructuring, asset impairments, and related costs in fiscal 2025 amounted to $33.2 million, down from $65.0 million in fiscal 2024 [482][484]. Cash Flow and Liquidity - Cash used in operating activities for fiscal 2025 was $165.8 million, a decrease from $282.0 million in fiscal 2024, primarily due to reduced operating losses and lower cash interest payments [547]. - Cash used in investing activities totaled $47.8 million in fiscal 2025, with $10.8 million for property, plant, and equipment improvements and $95.3 million for strategic investments, including the acquisition of Acreage's debt [549]. - Cash provided by financing activities was $148.7 million in fiscal 2025, driven by $385.4 million from common share issuances under ATM Programs, offset by $289.0 million in long-term debt repayments [552]. - Free cash flow for fiscal 2025 was an outflow of $176.6 million, an improvement from an outflow of $231.9 million in fiscal 2024, reflecting decreased cash used in operating activities [557]. - The company reported a net decrease in cash and cash equivalents of $56.5 million for fiscal 2025, compared to a decrease of $506.7 million in fiscal 2024 [545]. Debt and Financing - Total debt outstanding as of March 31, 2025, was $304.1 million, down from $597.2 million as of March 31, 2024, representing a decrease of approximately 49% [559]. - The total principal amount owing as of March 31, 2025, was $315.5 million, a reduction from $622.0 million at March 31, 2024, indicating a decrease of about 49% [559]. - The company entered into a Credit Agreement providing for a Credit Facility in the aggregate principal amount of US$750.0 million on March 18, 2021 [560]. - The company made an Optional Prepayment resulting in an aggregate principal reduction of $143.9 million (US$100.0 million) for a cash payment of $140.3 million (US$97.5 million) on March 31, 2025 [571]. - The company repurchased additional outstanding principal amounts under the Credit Facility resulting in an aggregate principal reduction of $73.3 million (US$54.5 million) for a cash payment of $69.6 million (US$51.8 million) on August 11, 2023, and September 14, 2023 [564]. Impairments and Restructuring - The company recognized a goodwill impairment loss totaling $1.7 billion for the cannabis operations reporting unit in the first quarter of fiscal 2023 [603]. - The company recognized a non-cash impairment of divestiture-related assets and employee restructuring costs contributing to the total restructuring costs [482]. - Impairment charges in fiscal 2024 totaled $79.5 million, including $42.1 million in goodwill impairment losses related to the Storz & Bickel reporting unit [527]. - The company recognized fair value changes on Canopy USA related assets resulting in increased expenses of $237.3 million in fiscal 2025 [490]. Strategic Initiatives - The company completed the acquisition of Acreage, owning 100% of the issued and outstanding shares, with 5,888,291 common shares issued to former shareholders of Acreage [432]. - The company has received EU-GMP certification at its Kincardine facility, enabling the export of certified medical cannabis to European markets [415]. - The company maintains agreements to supply all Canadian provinces and territories with adult-use products through established retail distribution systems [419]. - The company has developed a compassionate pricing program offering eligible low-income patients a 20% discount on regular prices of medical cannabis [419]. - The company has established an at-the-market equity program allowing it to issue and sell up to US$250 million of Canopy Shares [429].

Core Insights - Canopy Growth Corporation is expected to report a quarterly loss of 20 cents per share and projected revenue of $71.83 million for the fourth quarter [1] Financial Performance - The company made an optional early prepayment of $100 million under its senior secured term loan, resulting in annualized interest expense savings of approximately $13 million [2] - Canopy Growth shares fell 3.4% to close at $1.71 on the previous Thursday [2] Analyst Ratings - Zuanic & Associates analyst Pablo Zuanic initiated coverage on Canopy Growth with a Neutral rating, having an accuracy rate of 50% [7] - Piper Sandler analyst Michael Lavery maintained an Underweight rating and reduced the price target from $3 to $2, with an accuracy rate of 66% [7]

Core Viewpoint - A class action has been filed against Canopy Growth Corporation for allegedly misleading investors regarding its cost reduction measures and financial performance during a specific period [1][2]. Allegations - The complaint alleges that Canopy Growth Corporation failed to disclose significant costs associated with the production of Claybourne pre-rolled joints and indirect costs related to Storz & Bickel vaporizer devices, which negatively impacted gross margins and overall financial results [2]. - It is claimed that the company overstated the effectiveness of its cost reduction measures while downplaying issues related to gross margins [2]. Financial Impact - On February 7, 2025, Canopy announced disappointing financial results attributed to the costs from the Claybourne product launch and increased indirect costs, leading to a 27.24% drop in share price, closing at $2.02 [3]. Class Action Participation - Shareholders may be eligible to participate in the class action against Canopy Growth Corporation, with a deadline to contact Robbins LLP by June 3, 2025, for those wishing to serve as lead plaintiff [4]. Company Background - Robbins LLP is noted for its focus on shareholder rights litigation, aiming to help shareholders recover losses and improve corporate governance since 2002 [5].

NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Canopy Growth Corporation (NASDAQ: CGC) between May 30, 2024 and February 6, 2025, both dates inclusive (the "Class Period"), of the important June 3, 2025 lead plaintiff deadline. SO WHAT: If you purchased Canopy Growth securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangem ...

Canadian Gold Corp. Provides an Update on the Forest Fire Situation Near the Tartan MineMay 28, 2025 4:47 PM EDT | Source: Canadian Gold Corp.Flin Flon, Manitoba--(Newsfile Corp. - May 28, 2025) - Canadian Gold Corp. (TSXV: CGC) ("Canadian Gold" or the "Company") has temporarily suspended drilling operations at its Tartan Mine property near Flin Flon, Manitoba, due to a forest fire in the nearby vicinity."We have withdrawn our staff and continue to monitor our facilities remotely in accordance ...

Group 1 - Canopy Growth Corporation is facing a class action lawsuit for investors who purchased securities between May 30, 2024, and February 6, 2025, with a deadline to file a lead plaintiff motion by June 3, 2025 [1] - The law firm representing the investors, Portnoy Law Firm, offers complimentary case evaluations and encourages investors to discuss their legal rights [2] - Canopy Growth reported financial results for Q3 of fiscal year 2025, which fell short of consensus estimates, with a 400 basis point decline in gross margin to 32% due to increased costs from product launches and higher indirect costs [3]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Canopy Growth Corporation securities during the specified class period of the upcoming lead plaintiff deadline on June 3, 2025 [1] Group 1: Class Action Details - Investors who purchased Canopy Growth securities between May 30, 2024, and February 6, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6] - The lawsuit alleges that Canopy Growth made false and misleading statements regarding its financial health and cost management, which negatively impacted investors when the truth was revealed [5] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [4] - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [4] - In 2019, the firm secured over $438 million for investors, showcasing its effectiveness in representing clients [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Canopy Growth Corporation securities between May 30, 2024, and February 6, 2025, of the June 3, 2025, lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Canopy Growth securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by June 3, 2025 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that Canopy Growth made false and misleading statements regarding the costs associated with the launch of its Claybourne product and the impact on its gross margins [5]. - It is claimed that the company overstated the effectiveness of its cost reduction measures while downplaying financial issues, leading to investor damages when the true information became public [5].

NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Canopy Growth Corporation ("Canopy Growth Corporation" or the "Company") (NASDAQ: CGC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Canopy Growth Corporation investors who were adversely affected by alleged securities fraud between May 30, 2024 and February 6, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zl ...

Here Are Ways To Invest In Legal CannabisRight now, cannabis companies are still reporting Q1 2025 earnings, and for most things, are looking good. It is undeniable how well the cannabis industry is doing, even as the road ahead is still a tough one. Profits are being made and growth is occurring throughout the sector.But this has yet to help how marijuana stocks perform. There has been a volatile downturn for some time, and even with the progress of business pot stocks won’t move up. Now, with this success ...